Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients

Ngamkae Ruangvaravate, Karnthida Choojun, Benjawan Srikulsasitorn, Jatupol Chokboonpiem, Dechathon Asanatong, Supaporn Trakanwitthayarak Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Ngamkae RuangvaravateDepartment of Ophthalm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruangvaravate N, Choojun K, Srikulsasitorn B, Chokboonpiem J, Asanatong D, Trakanwitthayarak S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glaucoma ocular surface disease preservative-free tafluprost tear break up time Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3f4d43cba7d24a148f7bc2859b2d5c55
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f4d43cba7d24a148f7bc2859b2d5c55
record_format	dspace
spelling	oai:doaj.org-article:3f4d43cba7d24a148f7bc2859b2d5c552021-12-02T11:16:51ZOcular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients1177-5483https://doaj.org/article/3f4d43cba7d24a148f7bc2859b2d5c552020-10-01T00:00:00Zhttps://www.dovepress.com/ocular-surface-changes-after-switching-from-other-prostaglandins-to-ta-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Ngamkae Ruangvaravate, Karnthida Choojun, Benjawan Srikulsasitorn, Jatupol Chokboonpiem, Dechathon Asanatong, Supaporn Trakanwitthayarak Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Ngamkae RuangvaravateDepartment of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandTel +6624198037Fax +6624141232Email ngamkae1@gmail.comPurpose: To study ocular surface disease (OSD) changes after switching from preserved prostaglandin analogues monotherapy to preserved tafluprost and preservative-free (PF) tafluprost in primary open-angle glaucoma patients.Methods: Glaucoma patients treated with preserved prostaglandins (except tafluprost) monotherapy for at least 6 months, intraocular pressure (IOP) ≤ 22 mmHg, and diagnosed of OSD [≥ 1 criterion; tear break-up time (TBUT) ≤ 10 seconds, corneal fluorescein staining ≥grade 1] in both eyes were enrolled in a prospective, randomized, single-blinded study. All eligible patients were switched from preserved prostaglandin analogues monotherapy (latanoprost, bimatoprost, travoprost) to preserved tafluprost in one eye (group I) and PF-tafluprost in the other eye (group II) of the same patient by randomization. The symptoms of OSD were evaluated using the visual analogue scale, and lid inflammation, conjunctival hyperemia, TBUT, corneal fluorescein staining, and Schirmer I test were applied to assess the clinical signs. All parameters were evaluated before and then 6, 12, 24 weeks after switching the medications.Results: Thirty patients (80% women; mean age: 61.2 ± 11.5 years) were included. Baseline parameters were not different between the treatment groups. After switching therapies, TBUT was significantly increased in both groups (p = 0.002, p = 0.004, respectively); however, group II had better tear quality. Other symptoms and clinical signs of OSD were improved and IOP was controlled in both groups.Conclusion: Treatment with PF-tafluprost improves TBUT better than preserved tafluprost, suggesting that PF-tafluprost should be especially beneficial for patients with pre-existing OSD. Less or no preservative anti-glaucoma eye drops can restore and enhance the ocular surface in glaucoma patients.Keywords: glaucoma, ocular surface disease, preservative-free, tafluprost, tear break-up timeRuangvaravate NChoojun KSrikulsasitorn BChokboonpiem JAsanatong DTrakanwitthayarak SDove Medical Pressarticleglaucomaocular surface diseasepreservative-freetafluprosttear break up timeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 3109-3119 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma ocular surface disease preservative-free tafluprost tear break up time Ophthalmology RE1-994
spellingShingle	glaucoma ocular surface disease preservative-free tafluprost tear break up time Ophthalmology RE1-994 Ruangvaravate N Choojun K Srikulsasitorn B Chokboonpiem J Asanatong D Trakanwitthayarak S Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
description	Ngamkae Ruangvaravate, Karnthida Choojun, Benjawan Srikulsasitorn, Jatupol Chokboonpiem, Dechathon Asanatong, Supaporn Trakanwitthayarak Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Ngamkae RuangvaravateDepartment of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandTel +6624198037Fax +6624141232Email ngamkae1@gmail.comPurpose: To study ocular surface disease (OSD) changes after switching from preserved prostaglandin analogues monotherapy to preserved tafluprost and preservative-free (PF) tafluprost in primary open-angle glaucoma patients.Methods: Glaucoma patients treated with preserved prostaglandins (except tafluprost) monotherapy for at least 6 months, intraocular pressure (IOP) ≤ 22 mmHg, and diagnosed of OSD [≥ 1 criterion; tear break-up time (TBUT) ≤ 10 seconds, corneal fluorescein staining ≥grade 1] in both eyes were enrolled in a prospective, randomized, single-blinded study. All eligible patients were switched from preserved prostaglandin analogues monotherapy (latanoprost, bimatoprost, travoprost) to preserved tafluprost in one eye (group I) and PF-tafluprost in the other eye (group II) of the same patient by randomization. The symptoms of OSD were evaluated using the visual analogue scale, and lid inflammation, conjunctival hyperemia, TBUT, corneal fluorescein staining, and Schirmer I test were applied to assess the clinical signs. All parameters were evaluated before and then 6, 12, 24 weeks after switching the medications.Results: Thirty patients (80% women; mean age: 61.2 ± 11.5 years) were included. Baseline parameters were not different between the treatment groups. After switching therapies, TBUT was significantly increased in both groups (p = 0.002, p = 0.004, respectively); however, group II had better tear quality. Other symptoms and clinical signs of OSD were improved and IOP was controlled in both groups.Conclusion: Treatment with PF-tafluprost improves TBUT better than preserved tafluprost, suggesting that PF-tafluprost should be especially beneficial for patients with pre-existing OSD. Less or no preservative anti-glaucoma eye drops can restore and enhance the ocular surface in glaucoma patients.Keywords: glaucoma, ocular surface disease, preservative-free, tafluprost, tear break-up time
format	article
author	Ruangvaravate N Choojun K Srikulsasitorn B Chokboonpiem J Asanatong D Trakanwitthayarak S
author_facet	Ruangvaravate N Choojun K Srikulsasitorn B Chokboonpiem J Asanatong D Trakanwitthayarak S
author_sort	Ruangvaravate N
title	Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
title_short	Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
title_full	Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
title_fullStr	Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
title_full_unstemmed	Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
title_sort	ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3f4d43cba7d24a148f7bc2859b2d5c55
work_keys_str_mv	AT ruangvaravaten ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients AT choojunk ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients AT srikulsasitornb ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients AT chokboonpiemj ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients AT asanatongd ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients AT trakanwitthayaraks ocularsurfacechangesafterswitchingfromotherprostaglandinstotafluprostandpreservativefreetafluprostinglaucomapatients
_version_	1718396044286361600

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients

Ejemplares similares